MA54596A - Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant - Google Patents

Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant

Info

Publication number
MA54596A
MA54596A MA054596A MA54596A MA54596A MA 54596 A MA54596 A MA 54596A MA 054596 A MA054596 A MA 054596A MA 54596 A MA54596 A MA 54596A MA 54596 A MA54596 A MA 54596A
Authority
MA
Morocco
Prior art keywords
timapiprant
pharmaceutical composition
spherical agglomerates
agglomerates
spherical
Prior art date
Application number
MA054596A
Other languages
English (en)
Inventor
Marisa Pertile
Paolo Simone Tiseni
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA54596A publication Critical patent/MA54596A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA054596A 2018-12-27 2019-12-19 Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant MA54596A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18248081 2018-12-27

Publications (1)

Publication Number Publication Date
MA54596A true MA54596A (fr) 2022-04-06

Family

ID=65010443

Family Applications (2)

Application Number Title Priority Date Filing Date
MA054596A MA54596A (fr) 2018-12-27 2019-12-19 Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant
MA054595A MA54595A (fr) 2018-12-27 2019-12-19 Procédé de préparation d'agglomérats sphériques de timapiprant

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA054595A MA54595A (fr) 2018-12-27 2019-12-19 Procédé de préparation d'agglomérats sphériques de timapiprant

Country Status (4)

Country Link
US (2) US20220184059A1 (fr)
EP (2) EP3902794A1 (fr)
MA (2) MA54596A (fr)
WO (2) WO2020136093A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
US9668975B2 (en) * 2014-10-14 2017-06-06 PharmaDax Inc. Method of preparing drug agglomerate

Also Published As

Publication number Publication date
WO2020136093A1 (fr) 2020-07-02
US20220184060A1 (en) 2022-06-16
EP3902795A1 (fr) 2021-11-03
WO2020136095A1 (fr) 2020-07-02
US20220184059A1 (en) 2022-06-16
MA54595A (fr) 2022-04-06
EP3902794A1 (fr) 2021-11-03

Similar Documents

Publication Publication Date Title
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
IL279464A (en) Pharmaceutical formulation of odevixibat
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
MA49726A (fr) Formulation d'anticorps anti-cgrp
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
DK3634377T3 (da) Farmaceutisk formulering
MA43705A (fr) Formulation pharmaceutique
MA47516A (fr) Composition pharmaceutique
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
EP3639845C0 (fr) Composition pharmaceutique à base d'un complexe protéique d'il-15 et utilisations correspondantes
MA52704A (fr) Préparation pharmaceutique
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA53466A (fr) Formulation stable d'anticorps anti-osmr
MA49822A (fr) Combinaison pharmaceutique comprenant du ponesimod
MA44286A (fr) Formulation pharmaceutique de cinéol et d'amoxicilline
EP3297636A4 (fr) Composition pharmaceutique de co-cristaux à base de carboplatine et utilisation associée
DK3601277T3 (da) Farmaceutisk formulering
MA45126A (fr) Formulation pharmaceutique antifongique
MA54596A (fr) Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant